Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Maher Albitar"'
Autor:
Andrew Ip, Alexandra Della Pia, Gee Youn (Geeny) Kim, Jason Lofters, James Behrmann, Dylon Patel, Simone Kats, Jeffrey Justin Estella, Ivan De Dios, Wanlong Ma, Andrew L. Pecora, Andre H. Goy, Jamie Koprivnikar, James K. McCloskey, Maher Albitar
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionCytogenetic analysis is important for stratifying patients with various neoplasms. We explored the use of targeted next generation sequencing (NGS) in detecting chromosomal structural abnormalities or copy number variations (CNVs) in pati
Externí odkaz:
https://doaj.org/article/841f74756f494596ab6c774a50e1ff13
Autor:
Dennis D. Hickstein, Cynthia E. Dunbar, So Gun Hong, Thomas Winkler, Shiqin J. Yu, Danielle M. Townsley, Sergio A. Hassan, Elaine Kang, Xavi Guitart, Jizhong Zou, Vinh Dang, Stefan Cordes, Flavia S. Donaires, Steven M. Holland, Moonjung Jung, Maher Albitar, Amy P. Hsu
Publikováno v:
Blood Advances. 2:3553-3565
GATA2 deficiency is an inherited or sporadic genetic disorder characterized by distinct cellular deficiency, bone marrow failure, various infections, lymphedema, pulmonary alveolar proteinosis, and predisposition to myeloid malignancies resulting fro
Autor:
Farhad Ravandi, Koichi Takahashi, Feng Wang, Keyur P. Patel, Elias Jabbour, Steven M. Kornblau, Guillermo Garcia-Manero, Rashmi Kanagal-Shamanna, Zeev Estrov, Guillermo Montalban-Bravo, Rajyalakshmi Luthra, Sanam Loghavi, Jairo Matthews, Hagop M. Kantarjian, Maher Albitar, Nicholas J. Short, Ghayas C. Issa, Rita Assi, Miguel Franquiz, Wanlong Ma
Circulating cell-free DNA (ccfDNA) allows for noninvasive peripheral blood sampling of cancer-associated mutations and has established clinical utility in several solid tumors. We performed targeted next-generation sequencing of ccfDNA and bone marro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cb5a8d33bfea7e3e586e727e5ccd155
https://europepmc.org/articles/PMC7189293/
https://europepmc.org/articles/PMC7189293/
Autor:
Andre Goy, Jeffrey Estella, James K. McCloskey, Andrew Ip, Jamie Koprivnikar, Andrew L. Pecora, Ivan De Dios, Wanlong Ma, Maher Albitar
Publikováno v:
Blood. 138:3463-3463
Introduction: Cytogenetic analysis is important for stratifying patients with various myeloid neoplasms. It has been reported that whole-genome sequencing can be used as an alternative to cytogenetic analysis in acute myeloid leukemia (AML) and myelo
Autor:
Harvey G. Klein, Maher Albitar, Rebecca Coward, Sioban Keel, Sawa Ito, Rupa A Udani, Eleftheria Koklanaris, Prachi Jain, Minoo Battiwalla, A. John Barrett, Celina Montemayor-Garcia
Publikováno v:
Transfusion. 57:2136-2139
BACKGROUND Acquired copy-neutral loss of heterozygosity has been described in myeloid malignant progression with an otherwise normal karyotype. CASE REPORT A 65-year-old woman with MPL-mutated essential thrombocythemia and progression to myelofibrosi
Autor:
Maher Albitar, Fernanda Gutierrez-Rodrigues, Katherine R. Calvo, Valentina Giudice, Thomas Winkler, Phillip Scheinberg, Barbara Weinstein, Neal S. Young, Maria del Pilar Fernandez Ibanez, Cynthia E. Dunbar, Sachiko Kajigaya, Zhijie Wu, Danielle M. Townsley, Alana Vicente
Publikováno v:
Blood. 132:229-229
Eltrombopag (EPAG), a thrombopoietin receptor agonist, has been shown to improve hematopoiesis in patients with aplastic anemia (AA), but in MDS patients the effect of thrombopoietin mimetics in bone marrow function is still unclear. In this phase-2
Autor:
Zeev Estrov, Wanlong Ma, Xi Zhang, Hagop M. Kantarjian, Maher Albitar, Susan O'Brien, Xiuiang Wang
Publikováno v:
Leukemia Research. 35:526-533
The ubiquitin-proteasome system (UPS) plays a major role in the homeostasis of cellular protein. We demonstrate that each of the major hematologic diseases (AML, ALL, and MDS) has a specific and different plasma profile of UPS protein and enzymatic a
Autor:
Kimberly E. Hawkins, Maher Albitar, Neeraj Kumar Singh, Christopher R. Cogle, Amy Meacham, Shireen Vali, Chandan Kumar, Peter P. Sayeski, Taher Abbasi, Kaoru Tohyama, Sumanth Vasista, Rakhi Purushothaman Suseela, Elizabeth Wise, Leylah Drusbosky
Publikováno v:
Cancer Research. 78:4285-4285
Hypomethylating agents (HMA) and lenalidomide (LEN) are approved and used in the treatment of patients (pts) with MDS, though these drugs fail in most pts. No method exists to predict drug response beyond associating single actionable mutations with
Autor:
Iman Jilani, Michael J. Keating, Xi Zhang, Amber C. Donahue, Elihu H. Estey, Hagop M. Kantarjian, Susan O'Brien, Wanlong Ma, Maher Albitar, Mohammad Reza Sheikholeslami, Farhad Ravandi, Francis J. Giles
Publikováno v:
Cancer Biomarkers. 5:51-58
Roughly one-third of acute myeloid leukemia (AML) patients exhibit mutations in the nucleophosmin (NPM1) gene, and multiple studies have linked these mutations with a more favorable clinical outcome. We developed an assay for the detection of NPM1 mu
Autor:
Maher Albitar, Apostolia Maria Tsimberidou, Sherry Pierce, Sijin Wen, Razelle Kurzrock, Elihu H. Estey, Hagop M. Kantarjian
Publikováno v:
Cancer. 113:1605-1613
BACKGROUND. Tumor necrosis factor (TNF)-α and other cytokines are involved in the pathogenesis of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), but their prognostic significance in these diseases is unknown. In the curr